Research output per year
Research output per year
Personal profile
Headline
PROFESSOR | Medicine, Hematology and Medical Oncology PROFESSOR | Urology
Biography
Specialty Hematology-Oncology Certifications Medical Oncology Clinical Focus Bladder Cancer Kidney Cancer Primary Pulmonary Hypertension Prostate Cancer Testicular Tumors Urologic Cancers Education Residency, Internal Medicine Beth Israel Deaconess Medical Center- Harvard Medical School Fellowship, Medical Oncology Memorial Sloan-Kettering Cancer Center Biography Dr. Galsky specializes in the care of patients with genitourinary malignancies (bladder, prostate, kidney, and testicular cancers). His research focuses on the development of novel treatments for these cancers and he has published extensively in this area. He serves as Director of Genitourinary Medical Oncology at the Tisch Cancer Institute. Awards 2003 - American Society of Clinical Oncology Merit Award 1998 - Medical Calss of 1928 Award (Tufts School of Medicine, Excellence in Anatomy) 1998 - Leon Levinson Prize (Tufts School of Medicine, Excellence in Physiology) 1997 - Alpha Omega Alpha Honor Society
Fingerprint
Dive into the research topics where Matthew Galsky is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274☆
Galsky, M. D., Gschwend, J. E., Milowsky, M. I., Schenker, M., Valderrama, B. P., Tomita, Y., Bamias, A., Lebret, T., Shariat, S. F., Park, S. H., Agerbaek, M., Jha, G., Stenner, F., Ye, D., Giudici, F., Connors, J., Gupta, S., Chhibber, A., Zhang, J. & Bajorin, D. F. & 1 others, , Jan 2026, In: Annals of Oncology. 37, 1, p. 69-78 10 p.Research output: Contribution to journal › Article › peer-review
Open Access25 Scopus citations -
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers
McKay, R. R., Pal, S., Xie, W., Aggen, D., Albiges, L., Apolo, A., Atkins, M. B., Bangs, R., Beckermann, K. E., Bellmunt, J., Berg, S. A., Bilen, M. A., Braun, D., Carlo, M. I., Efstathiou, J., Galsky, M., Grivas, P., Gupta, S., Haas, N. & Hakimi, A. A. & 34 others, , 1 Jan 2026, In: Ca-A Cancer Journal for Clinicians. 76, 1, e70052.Research output: Contribution to journal › Review article › peer-review
Open Access5 Scopus citations -
A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial
Galsky, M. D., Mantia, C., Bowden, M., Bellmunt, J., Garmezy, B., Iyer, G., Petrylak, D. P., Rasco, D., Gupta, S., Rodriguez-Rivera, I., Mikhailov, Y., Joshi, A., Nguyen, P. A., Kakrecha, B., Tepper, J., Costa, A. M., McCrone, C., Rossi, A. P., Mertz, J. A. & Gjini, E. & 3 others, , Apr 2026, In: Nature Medicine. 32, 4, p. 1249-1256 8 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
A Tumor-Promoting Inflammatory SPP1+ Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer
Tran, M. A., Cho, B. A., Izadmehr, S., Yoo, S. K., Youssef, D., Anker, J. F., Farkas, A. M., Figueiredo, I., Lee, K., Ananthanarayanan, A., Balan, S., Onkar, S., Banchereau, R., Gupta, S., Chhibber, A., Wang, L., Beaumont, K. G., Li, Z., Garcia-Barros, M. & Bicak, M. & 18 others, , Jun 2026, In: Cancer Discovery. 16, 6, p. 1126-1151 26 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Evolving Trends in Latin American Participation in Global Oncology Clinical Trials: A Decade of Phase III Activity (2013-2022)
Paredes de la Fuente, R., Karol, A. B., Markus, A., Argulian, A., Omori, R., Fujiwara, Y., Joshi, H., Doroshow, D. B. & Galsky, M. D., 1 Feb 2026, In: JCO Global Oncology. 12, p. e2500411Research output: Contribution to journal › Article › peer-review
Open Access
Press/Media
-
Natera, Inc. (NASDAQ:NTRA) extends higher by 7.1% in Week 26 of 2026: Latest News and Company Communication
2/07/26
1 item of Media coverage
Press/Media
-
Case 3: Perioperative Strategies for a Patient With Muscle-Invasive Bladder Cancer and Borderline Renal Function
29/06/26
1 item of Media coverage
Press/Media
-
Case 2: Adjuvant Therapy in a Patient With Cisplatin-Ineligible, Pathologic Node-Positive Muscle-Invasive Bladder Cancer
29/06/26
1 item of Media coverage
Press/Media
-
NCCN Updates Bladder Cancer Guidelines for ctDNA MRD Testing
23/06/26
1 item of Media coverage
Press/Media